Covid-19 roundup: Can­cer drug re­search takes a big hit, sur­vey finds; Chaot­ic remde­sivir dis­tri­b­u­tion con­tin­ues to anger doc­tors

Emerg­ing da­ta sug­gest that the Covid-19 pan­dem­ic has led to the sus­pen­sion of over 1,000 tri­als glob­al­ly — and it looks like can­cer re­search in the Unit­ed States could be a big part of that col­lat­er­al dam­age.

The non-prof­it or­ga­ni­za­tion Amer­i­can Can­cer So­ci­ety (ACS) — which funds can­cer re­search, pa­tient sup­port, ed­u­ca­tion, and de­tec­tion and treat­ment — asked 744 groups that are cur­rent­ly con­duct­ing re­search us­ing ACS-award­ed grants about the sta­tus of their projects, of which 488 re­spond­ed. The re­sults were chill­ing: More than half the re­spon­dents said their re­search had been halt­ed as a re­sult of the coro­n­avirus pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER